Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DOXEPIN HCL

12 general benefit · 8 not a benefit

Other products in the same Health Canada class (N06AA) — coverage varies; not interchangeable

  • Amitriptyline (Elavil): general benefit
  • Clomipramine (Anafranil Tab): general benefit
  • Desipramine (Pertofrane): general benefit, Not a benefit
  • Imipramine (Tofranil): general benefit, Not a benefit
  • Nortriptyline (Aventyl): general benefit
  • Trimipramine (Surmontil): general benefit, Not a benefit

17 more in the class list below

Apo-Doxepin · DIN 02049996 · 10mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Doxepin · DIN 02049996 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-01-09 · brand APO-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Doxepin: Formulary list price $0.1019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15118 · Verify on the e-Formulary ↗ (DIN 02049996)

Source record
DIN 02049996: Apo-Doxepin Raw flags: sec3=Y Item: 281604010; group id 458; item number 1143; lccId None; manufacturer id APX Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1019; ministry $0.1019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02049996 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15118
Interchangeable products
Jamp Doxepin · DIN 02559250 · $0.1019 Mar-Doxepin · DIN 02559080 · $0.1019 Sinequan · DIN 00024325 · $0.1019
Shortage status: discontinued (2018-11-19, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049996
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Doxepin · DIN 02559250 · 10mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Doxepin · DIN 02559250 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-05-22 · brand JAMP DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Doxepin: Formulary list price $0.1019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106242 · Verify on the e-Formulary ↗ (DIN 02559250)

Source record
DIN 02559250: Jamp Doxepin Raw flags: sec3=Y Item: 281604010; group id 458; item number 1143; lccId None; manufacturer id JPC Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1019; ministry $0.1019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559250 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106242
Interchangeable products
Apo-Doxepin · DIN 02049996 · $0.1019 Mar-Doxepin · DIN 02559080 · $0.1019 Sinequan · DIN 00024325 · $0.1019
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559250
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Doxepin · DIN 02559080 · 10mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Doxepin · DIN 02559080 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-09-29 Health Canada: Marketed since 2025-08-06 · brand MAR-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Doxepin: Formulary list price $0.1019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106227 · Verify on the e-Formulary ↗ (DIN 02559080)

Source record
DIN 02559080: Mar-Doxepin Raw flags: sec3=Y Item: 281604010; group id 458; item number 1143; lccId None; manufacturer id MAR Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1019; ministry $0.1019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559080 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106227
Interchangeable products
Apo-Doxepin · DIN 02049996 · $0.1019 Jamp Doxepin · DIN 02559250 · $0.1019 Sinequan · DIN 00024325 · $0.1019
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559080
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sinequan · DIN 00024325 · 10mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sinequan · DIN 00024325 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-12-29 · brand SINEQUAN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 10 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=944 · Verify on the e-Formulary ↗ (DIN 00024325)

Source record
DIN 00024325: Sinequan Raw flags: sec3=Y Item: 281604010; group id 458; item number 1143; lccId None; manufacturer id AAP Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.4075; ministry $0.1019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=944
Interchangeable products
Apo-Doxepin · DIN 02049996 · $0.1019 Jamp Doxepin · DIN 02559250 · $0.1019 Mar-Doxepin · DIN 02559080 · $0.1019
Shortage status: resolved shortage (ended 2025-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00024325
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Doxepin · DIN 02050005 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Doxepin · DIN 02050005 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2025-11-13 · brand APO-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Doxepin: Formulary list price $0.1250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15106 · Verify on the e-Formulary ↗ (DIN 02050005)

Source record
DIN 02050005: Apo-Doxepin Raw flags: sec3=Y Item: 281604009; group id 458; item number 1144; lccId None; manufacturer id APX Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1250; ministry $0.1250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02050005 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15106
Interchangeable products
Jamp Doxepin · DIN 02559269 · $0.1250 Mar-Doxepin · DIN 02559099 · $0.1250 Sinequan · DIN 00024333 · $0.1250
Shortage status: discontinued (2018-10-23, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050005
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Doxepin · DIN 02559269 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Doxepin · DIN 02559269 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-05-22 · brand JAMP DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Doxepin: Formulary list price $0.1250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106243 · Verify on the e-Formulary ↗ (DIN 02559269)

Source record
DIN 02559269: Jamp Doxepin Raw flags: sec3=Y Item: 281604009; group id 458; item number 1144; lccId None; manufacturer id JPC Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1250; ministry $0.1250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559269 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106243
Interchangeable products
Apo-Doxepin · DIN 02050005 · $0.1250 Mar-Doxepin · DIN 02559099 · $0.1250 Sinequan · DIN 00024333 · $0.1250
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559269
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Doxepin · DIN 02559099 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Doxepin · DIN 02559099 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-09-29 Health Canada: Marketed since 2025-08-06 · brand MAR-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 25 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Doxepin: Formulary list price $0.1250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106228 · Verify on the e-Formulary ↗ (DIN 02559099)

Source record
DIN 02559099: Mar-Doxepin Raw flags: sec3=Y Item: 281604009; group id 458; item number 1144; lccId None; manufacturer id MAR Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.1250; ministry $0.1250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559099 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106228
Interchangeable products
Apo-Doxepin · DIN 02050005 · $0.1250 Jamp Doxepin · DIN 02559269 · $0.1250 Sinequan · DIN 00024333 · $0.1250
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559099
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sinequan · DIN 00024333 · 25mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sinequan · DIN 00024333 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-02-01 · brand SINEQUAN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 25 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=945 · Verify on the e-Formulary ↗ (DIN 00024333)

Source record
DIN 00024333: Sinequan Raw flags: sec3=Y Item: 281604009; group id 458; item number 1144; lccId None; manufacturer id AAP Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.5000; ministry $0.1250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024333 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=945
Interchangeable products
Apo-Doxepin · DIN 02050005 · $0.1250 Jamp Doxepin · DIN 02559269 · $0.1250 Mar-Doxepin · DIN 02559099 · $0.1250
Shortage status: resolved shortage (ended 2025-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00024333
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Doxepin · DIN 02050013 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Doxepin · DIN 02050013 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2025-11-13 · brand APO-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Doxepin: Formulary list price $0.2319/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2319 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15107 · Verify on the e-Formulary ↗ (DIN 02050013)

Source record
DIN 02050013: Apo-Doxepin Raw flags: sec3=Y Item: 281604008; group id 458; item number 1145; lccId None; manufacturer id APX Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2319; ministry $0.2319 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02050013 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15107
Interchangeable products
Jamp Doxepin · DIN 02559277 · $0.2319 Mar-Doxepin · DIN 02559102 · $0.2319 Sinequan · DIN 00024341 · $0.2319
Shortage status: discontinued (2018-12-18, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050013
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Doxepin · DIN 02559277 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Doxepin · DIN 02559277 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-05-20 · brand JAMP DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Doxepin: Formulary list price $0.2319/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2319 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106244 · Verify on the e-Formulary ↗ (DIN 02559277)

Source record
DIN 02559277: Jamp Doxepin Raw flags: sec3=Y Item: 281604008; group id 458; item number 1145; lccId None; manufacturer id JPC Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2319; ministry $0.2319 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559277 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106244
Interchangeable products
Apo-Doxepin · DIN 02050013 · $0.2319 Mar-Doxepin · DIN 02559102 · $0.2319 Sinequan · DIN 00024341 · $0.2319
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559277
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Doxepin · DIN 02559102 · 50mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Doxepin · DIN 02559102 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-09-29 Health Canada: Marketed since 2025-08-06 · brand MAR-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 50 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Doxepin: Formulary list price $0.2319/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2319 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106229 · Verify on the e-Formulary ↗ (DIN 02559102)

Source record
DIN 02559102: Mar-Doxepin Raw flags: sec3=Y Item: 281604008; group id 458; item number 1145; lccId None; manufacturer id MAR Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2319; ministry $0.2319 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559102 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106229
Interchangeable products
Apo-Doxepin · DIN 02050013 · $0.2319 Jamp Doxepin · DIN 02559277 · $0.2319 Sinequan · DIN 00024341 · $0.2319
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559102
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sinequan · DIN 00024341 · 50mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sinequan · DIN 00024341 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-03-13 · brand SINEQUAN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 50 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2319 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=946 · Verify on the e-Formulary ↗ (DIN 00024341)

Source record
DIN 00024341: Sinequan Raw flags: sec3=Y Item: 281604008; group id 458; item number 1145; lccId None; manufacturer id AAP Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.9274; ministry $0.2319 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024341 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=946
Interchangeable products
Apo-Doxepin · DIN 02050013 · $0.2319 Jamp Doxepin · DIN 02559277 · $0.2319 Mar-Doxepin · DIN 02559102 · $0.2319
Shortage status: resolved shortage (ended 2022-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00024341
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Doxepin · DIN 02050021 · 75mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Doxepin · DIN 02050021 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2025-11-13 · brand APO-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 75 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15108 · Verify on the e-Formulary ↗ (DIN 02050021)

Source record
DIN 02050021: Apo-Doxepin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604028; group id 458; item number 1146; lccId None; manufacturer id APX Source form: Cap; strength: 75mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.1363; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02050021 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15108
Interchangeable products
Jamp Doxepin · DIN 02559285 · not recorded Mar-Doxepin · DIN 02559110 · not recorded Sinequan · DIN 00400750 · not recorded
Shortage status: discontinued (2019-01-30, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050021
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Doxepin · DIN 02559285 · 75mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Doxepin · DIN 02559285 Manufacturer: Jamp Pharma Corporation; listing date 2026-03-31 Health Canada: Marketed since 2026-05-22 · brand JAMP DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 75 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106245 · Verify on the e-Formulary ↗ (DIN 02559285)

Source record
DIN 02559285: Jamp Doxepin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604028; group id 458; item number 1146; lccId None; manufacturer id JPC Source form: Cap; strength: 75mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.1363; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559285 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106245
Interchangeable products
Apo-Doxepin · DIN 02050021 · not recorded Mar-Doxepin · DIN 02559110 · not recorded Sinequan · DIN 00400750 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559285
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Doxepin · DIN 02559110 · 75mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Doxepin · DIN 02559110 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-09-29 Health Canada: Marketed since 2025-08-06 · brand MAR-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 75 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106230 · Verify on the e-Formulary ↗ (DIN 02559110)

Source record
DIN 02559110: Mar-Doxepin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604028; group id 458; item number 1146; lccId None; manufacturer id MAR Source form: Cap; strength: 75mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.1363; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559110 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106230
Interchangeable products
Apo-Doxepin · DIN 02050021 · not recorded Jamp Doxepin · DIN 02559285 · not recorded Sinequan · DIN 00400750 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559110
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sinequan · DIN 00400750 · 75mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sinequan · DIN 00400750 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-11-12 · brand SINEQUAN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 75 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Sinequan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2780 · Verify on the e-Formulary ↗ (DIN 00400750)

Source record
DIN 00400750: Sinequan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604028; group id 458; item number 1146; lccId None; manufacturer id AAP Source form: Cap; strength: 75mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00400750 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2780
Interchangeable products
Apo-Doxepin · DIN 02050021 · not recorded Jamp Doxepin · DIN 02559285 · not recorded Mar-Doxepin · DIN 02559110 · not recorded
Shortage status: resolved shortage (ended 2025-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00400750
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Doxepin · DIN 02050048 · 100mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Doxepin · DIN 02050048 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2025-11-13 · brand APO-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15104 · Verify on the e-Formulary ↗ (DIN 02050048)

Source record
DIN 02050048: Apo-Doxepin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604027; group id 458; item number 1147; lccId None; manufacturer id APX Source form: Cap; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.4944; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02050048 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15104
Interchangeable products
Jamp Doxepin · DIN 02559293 · not recorded Mar-Doxepin · DIN 02559129 · not recorded Sinequan · DIN 00326925 · not recorded
Shortage status: discontinued (2018-12-04, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050048
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Doxepin · DIN 02559293 · 100mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Doxepin · DIN 02559293 Manufacturer: Jamp Pharma Corporation; listing date 2026-03-31 Health Canada: Marketed since 2026-05-22 · brand JAMP DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106246 · Verify on the e-Formulary ↗ (DIN 02559293)

Source record
DIN 02559293: Jamp Doxepin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604027; group id 458; item number 1147; lccId None; manufacturer id JPC Source form: Cap; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.4944; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559293 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106246
Interchangeable products
Apo-Doxepin · DIN 02050048 · not recorded Mar-Doxepin · DIN 02559129 · not recorded Sinequan · DIN 00326925 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559293
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Doxepin · DIN 02559129 · 100mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Doxepin · DIN 02559129 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-09-29 Health Canada: Marketed since 2025-08-06 · brand MAR-DOXEPIN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 100 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106231 · Verify on the e-Formulary ↗ (DIN 02559129)

Source record
DIN 02559129: Mar-Doxepin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604027; group id 458; item number 1147; lccId None; manufacturer id MAR Source form: Cap; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.4944; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559129 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106231
Interchangeable products
Apo-Doxepin · DIN 02050048 · not recorded Jamp Doxepin · DIN 02559293 · not recorded Sinequan · DIN 00326925 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559129
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sinequan · DIN 00326925 · 100mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sinequan · DIN 00326925 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-11-12 · brand SINEQUAN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 100 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Sinequan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2049 · Verify on the e-Formulary ↗ (DIN 00326925)

Source record
DIN 00326925: Sinequan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604027; group id 458; item number 1147; lccId None; manufacturer id AAP Source form: Cap; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00326925 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2049
Interchangeable products
Apo-Doxepin · DIN 02050048 · not recorded Jamp Doxepin · DIN 02559293 · not recorded Mar-Doxepin · DIN 02559129 · not recorded
Shortage status: resolved shortage (ended 2025-09-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00326925
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap

TRIMIPRAMINE

· 10 products · Listed, not a benefit (5), General benefit (5) · strengths: 75mg, 12.5mg, 25mg, 50mg, 100mg · Cap, Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS The antidepressant and anxiolytic properties of SINEQUAN (doxepin HCl) have been found to be of value in the drug treatment of: 1. Psychoneurotic patients with anxiety and/or depressive reactions; Anxiety neurosis associated with somatic disorders; Alcoholic patients with anxiety and/or depression. 2. Psychotic depression, including manic-depressive illness (depressed type) and involutional melancholia. CLINICAL USE Controlled clinical trials have confirmed that SINEQUAN (doxepin HCl) is an effective psychotropic agent with antidepressant and anxiolytic properties. SINEQUAN has been found useful in alleviating manifest anxiety in neurotic patients including those with somatic disorders. It has also been found useful in patients with neurotic depression, including those with mixed anxiety and depression. Patients with endogenous or psychotic depression, including manic-depressive illness (depressed type), and involutional melancholia, have also been reported to respond favorably to SINEQUAN. As adjunctive medication, … https://pdf.hres.ca/dpd_pm/00047238.PDF PM date: August 31, 2018 Source product: SINEQUAN; DIN 00024325; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Doxepin · DIN 02049996 Shortage status: discontinued (2018-11-19, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049996

Check this DIN again

Apo-Doxepin · DIN 02050005 Shortage status: discontinued (2018-10-23, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050005

Check this DIN again

Apo-Doxepin · DIN 02050013 Shortage status: discontinued (2018-12-18, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050013

Check this DIN again

Apo-Doxepin · DIN 02050021 Shortage status: discontinued (2019-01-30, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050021

Check this DIN again

Apo-Doxepin · DIN 02050048 Shortage status: discontinued (2018-12-04, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02050048

Check this DIN again

Other review policies

For Apo-Doxepin, Jamp Doxepin, Mar-Doxepin, Sinequan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026